Your browser doesn't support javascript.
loading
Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption.
Bailey, Shivani; Ferraresso, Marta; Alonso-Crisostomo, Luz; Ward, Dawn; Smith, Stephen; Nicholson, James C; Saini, Harpreet; Enright, Anton J; Scarpini, Cinzia G; Coleman, Nicholas; Murray, Matthew J.
Afiliação
  • Bailey S; Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
  • Ferraresso M; Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
  • Alonso-Crisostomo L; Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
  • Ward D; Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
  • Smith S; Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
  • Nicholson JC; Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
  • Saini H; Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
  • Enright AJ; Department of Paediatrics, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
  • Scarpini CG; EMBL-European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Coleman N; Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
  • Murray MJ; Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
Br J Cancer ; 129(9): 1451-1461, 2023 10.
Article em En | MEDLINE | ID: mdl-37789102
BACKGROUND: MiR-371~373 and miR-302/367 cluster over-expression occurs in all malignant germ cell tumours (GCTs), regardless of age (paediatric/adult), site (gonadal/extragonadal), or subtype [seminoma, yolk sac tumour (YST), embryonal carcinoma (EC)]. Six of eight microRNAs from these clusters contain the seed sequence 'AAGUGC', determining mRNA targeting. Here we sought to identify the significance of these observations by targeting these microRNAs functionally. METHODS: We targeted miR-371~373 and/or miR-302/367 clusters in malignant GCT cell lines, using CRISPR-Cas9, gapmer primary miR-302/367 transcript inhibition, and peptide nucleic acid (PNA) or locked nucleic acid (LNA)-DNA inhibition targeting miR-302a-d-3p, and undertook relevant functional assays. RESULTS: MiR-302/367 cluster microRNAs made the largest contribution to AAGUGC seed abundance in malignant GCT cells, regardless of subtype (seminoma/YST/EC). Following the unsuccessful use of CRISPR-Cas9, gapmer, and PNA systems, LNA-DNA-based targeting resulted in growth inhibition in seminoma and YST cells. This was associated with the de-repression of multiple mRNAs targeted by AAGUGC seed-containing microRNAs, with pathway analysis confirming predominant disruption of Rho-GTPase signalling, vesicle organisation/transport, and cell cycle regulation, findings corroborated in clinical samples. Further LNA-DNA inhibitor studies confirmed direct cell cycle effects, with an increase of cells in G0/G1-phase and a decrease in S-phase. CONCLUSION: Targeting of specific miR-371~373 and miR-302/367 microRNAs in malignant GCTs demonstrated their functional significance, with growth inhibition mediated through cell cycle disruption.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Seminoma / Neoplasias Embrionárias de Células Germinativas / MicroRNAs Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adult / Child / Humans / Male Idioma: En Revista: Br J Cancer Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Seminoma / Neoplasias Embrionárias de Células Germinativas / MicroRNAs Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adult / Child / Humans / Male Idioma: En Revista: Br J Cancer Ano de publicação: 2023 Tipo de documento: Article